Circulating microRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective study

PURPOSE: Immune-checkpoint inhibitors (ICIs) have improved the survival of NSCLC patients. However, only a subset of patients benefit from ICIs, and the role of PD-L1 as predictive biomarker is still debated. A plasma immune-related microRNA-signature classifier (MSC) was established in lung cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Boeri, Mattia, Milione, Massimo, Proto, Claudia, Signorelli, Diego, Lo Russo, Giuseppe, Galeone, Carlotta, Verri, Carla, Mensah, Mavis, Centonze, Giovanni, Martinetti, Antonia, Sottotetti, Elisa, Pastorino, Ugo, Garassino, Marina C., Sozzi, Gabriella
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445748/
https://ncbi.nlm.nih.gov/pubmed/30617131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1981
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados